A solid-phase, enzyme-linked immunosorbent assay for a human lung tumor-associated antigen

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Development of sensitive diagnostic tools for lung cancer is crucial.
• Existing assays may not fully capture the dynamics of tumor markers.
• Lung tumor-associated antigen (LTA) is a potential biomarker for lung cancer.

Purpose of the Study:

• To develop and validate a solid-phase enzyme-linked immunosorbent assay (ELISA) for detecting human lung tumor-associated antigen (LTA).
• To evaluate the assay's ability to differentiate between lung tumor and normal lung tissue.
• To monitor LTA levels in lung cancer patients and compare them with carcinoembryonic antigen (CEA) levels.

Main Methods:

• A solid-phase ELISA was established using immobilized LTA and goat antiserum.
• Detection involved a multi-step process including biotinylated antibodies, avidin-glucose oxidase conjugate, and peroxidase substrate.
• Assay sensitivity and specificity were tested, and LTA levels were monitored in lung cancer patients.

Main Results:

• The ELISA could detect less than 1 ng of LTA and effectively distinguish tumor extracts from normal lung tissue.
• Normal human serum showed inhibitory effects only at high concentrations, suggesting LTA levels of 100-200 ng/ml.
• In three monitored lung cancer patients, LTA levels increased dramatically 2-4 months before death, exceeding 3,000 ng/ml in two cases, while CEA levels remained relatively stable.

Conclusions:

• The developed ELISA is a sensitive and specific method for quantifying human lung tumor-associated antigen (LTA).
• Elevated LTA levels show a strong correlation with disease progression and imminent mortality in lung cancer patients.
• LTA appears to be a more sensitive indicator of advanced lung cancer progression than CEA in the studied patients.